Beijing Konruns Pharmaceutical (603590) Fundamentals 2026 — P/E 31.0x, Revenue Analysis | SniperIQ
Beijing Konruns Pharmaceutical (603590) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥5.2B, trading at ¥32.83 on the SHH. This SniperIQ fundamentals page covers Beijing Konruns Pharmaceutical's valuation (P/E 31.0x, P/B 1.6x), profitability (net margin 18.4%), revenue (¥915M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Beijing Konruns Pharmaceutical's market cap?
Beijing Konruns Pharmaceutical (603590) has a market capitalization of approximately ¥5.2B, trading at ¥32.83 on the SHH. Market cap moves with the live share price.
What is Beijing Konruns Pharmaceutical's P/E ratio?
Beijing Konruns Pharmaceutical's trailing twelve-month P/E ratio is 31.0x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Beijing Konruns Pharmaceutical?
Beijing Konruns Pharmaceutical runs a net profit margin of 18.4%, a gross margin of 89.8%, and an operating margin of 22.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Beijing Konruns Pharmaceutical generate?
Beijing Konruns Pharmaceutical reported revenue of ¥915M for fiscal year 2025, with net income of ¥166M and earnings per share (EPS) of 1.05. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Beijing Konruns Pharmaceutical pay a dividend?
Beijing Konruns Pharmaceutical offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Beijing Konruns Pharmaceutical financially healthy?
Beijing Konruns Pharmaceutical carries a debt-to-equity ratio of 0.10x and a current ratio of 3.05x, with a market beta of 0.45. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Beijing Konruns Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Beijing Konruns Pharmaceutical (603590) the key facts are: market cap ¥5.2B, P/E 31.0x, revenue ¥915M, 52-week range 27.33-67.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Beijing Konruns Pharmaceutical's full fundamentals live
Get Beijing Konruns Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.